Skip to main content
European Commission logo
Enterprise Europe Network

Targeted Nanoantibiotic for Osteomylitis Treatment

Summary

Profile Type
  • Technology offer
POD Reference
TOTR20240327016
Term of Validity
27 March 2024 - 27 March 2025
Company's Country
  • Turkey
Type of partnership
  • Commercial agreement with technical assistance
Targeted Countries
  • Italy
  • United Kingdom
  • Denmark
  • Norway
  • France
  • Sweden
  • Greece
  • Belgium
  • Germany
  • Poland
  • Switzerland
  • Bulgaria
  • Spain
  • Netherlands
  • Austria
  • Luxembourg
Contact the EEN partner nearest to you for more information.
Find my local partner

General information

Short Summary
Turkish researchers are seeking to transfer the patent for magnetically targeted and in vivo proven effective nanoantibiotic for the treatment of osteomyelitis in the medical sector, or to find a manufacturing company. This system is available for patent transfer or partnership with a manufacturer.
Full Description
The invention is a targeted drug delivery system for treating osteomyelitis. It uses gentamicin loaded and gelatin coated magnetite nanoparticles. This system reduces drug toxicity and resistance by delivering antibiotics directly to the infected area. The nanoparticles are biodegradable and are directed to the infection site using an external magnetic field. In vivo studies have shown promising results in animal models.
The inventors are in search of a company that can acquire the patent rights to their product. Additionally, the inventors intend to secure partnering and licensing agreements globally and across the various health and wellness sectors. The company will work with route-to-market partners to adapt the process to optimize the efficacy of prototype.
Advantages and Innovations
By developing biodegradable and magnetic targeted antibiotics delivery system for treating osteomyelitis, drug resistance and toxicity are reduced, and besides this, therapeutic efficiency is increased. The inventors have deep know-how and a filed patent for nanoantibiotic in osteomyelitis.
Stage of Development
  • Lab tested
Sustainable Development Goals
  • Goal 9: Industry, Innovation and Infrastructure
  • Goal 3: Good Health and Well-being
  • Goal 12: Responsible Consumption and Production

Partner Sought

Expected Role of a Partner
Partnership through a commercial agreement with technical assistance, including licensing opportunities is sought. The ideal partner is a company that want to take over the patent.
The Turkish inventors are open to collaborate under licensed manufacturing and marketing of the prototype.
Type and Size of Partner
  • Big company
Type of partnership
  • Commercial agreement with technical assistance

Dissemination

Technology keywords
  • 06001015 - Pharmaceutical Products / Drugs
Market keywords
  • 05007002 - Pharmaceuticals/fine chemicals
Targeted countries
  • Italy
  • United Kingdom
  • Denmark
  • Norway
  • France
  • Sweden
  • Greece
  • Belgium
  • Germany
  • Poland
  • Switzerland
  • Bulgaria
  • Spain
  • Netherlands
  • Austria
  • Luxembourg